Home /
Chemotherapy – University of Chicago Medical Center – USA
|
|
| Description: |
| Patients: This Phase II study involved 17 patients with malignant mesothelioma.
Treatment: The treatment consisted of the chemotherapy drug, gemcitabine. Toxicity: Two patients died without documentation of progressive disease and at least one of these deaths was considered related to drug toxicity and disease progression. In addition, grade 3-4 toxicities included hematologic, infection, dyspnea, edema, malaise/fatigue, cerebellar, cardiac dysrhythmia, and hyponatremia. Results: There were no complete or partial responses and the median survival time was 4.7 months. Correspondence: Hedy L. Kindler, MD |
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."